JP Morgan Chase
BLPH

JP Morgan Chase’s Bellerophon Therapeutics, Inc. BLPH Stock Holding History

JP Morgan Chase’s Portfolio BLPH Stock Details BLPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-100
Closed – – 7558
2022
Q4 		$0 Sell
100
-8
-7% -$8 ﹤0.01% 7399
2022
Q3 		$0 Buy
108
+8
+8% +$10 ﹤0.01% 7192
2022
Q2 		$0 Hold
100
– – ﹤0.01% 7243
2022
Q1 		$0 Hold
100
– – ﹤0.01% 7342
2021
Q4 		$0 Hold
100
– – ﹤0.01% 7299
2021
Q3 		$0 Sell
100
-6,407
-98% -$26.7K ﹤0.01% 7081
2021
Q2 		$31K Buy
6,507
+4,607
+242% +$20.7K ﹤0.01% 5858
2021
Q1 		$10K Sell
1,900
-8,801
-82% -$61.3K ﹤0.01% 5803
2020
Q4 		$72K Buy
10,701
+7,740
+261% +$63.4K ﹤0.01% 5074
2020
Q3 		$29K Buy
2,961
+67
+2% +$788 ﹤0.01% 5083
2020
Q2 		$37K Buy
+2,894
New +$40.5K ﹤0.01% 4921
2018
Q3 		– Sell
-15,825
Closed -$574K – 5928
2018
Q2 		$574K Buy
15,825
+14,334
+961% +$496K ﹤0.01% 4111
2018
Q1 		$47K Buy
+1,491
New +$47.4K ﹤0.01% 4844

Other funds holding BLPH

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase's BLPH Position: Q1 2023 in Review

JP Morgan Chase sold out of Bellerophon Therapeutics, Inc. (BLPH) in Q1 2023, closing a stake of 100 shares.

JP Morgan Chase first reported a position in BLPH in Q1 2018 and held it in 13 quarters. The position peaked at $574K in Q2 2018. 19 funds tracked by Wall St. Rank hold BLPH as of Q1 2023.

  • JP Morgan Chase reported no remaining Bellerophon Therapeutics, Inc. position as of Q1 2023 after selling out during the quarter.
  • JP Morgan Chase sold 100 Bellerophon Therapeutics, Inc. shares in Q1 2023.
  • JP Morgan Chase first reported a position in Bellerophon Therapeutics, Inc. in Q1 2018 and held it in 13 quarters.
  • JP Morgan Chase's Bellerophon Therapeutics, Inc. position peaked at $574K in Q2 2018.
  • 19 funds tracked by Wall St. Rank held Bellerophon Therapeutics, Inc. as of Q1 2023.

Based on JP Morgan Chase's 13F filing for Q1 2023, filed 11 May 2023.